phase readout
saveNCT04602598: Zanubrutinib in Patients With IgG4-Related Disease
community read0 votes
Sponsor: Matthew C. Baker. Phase: PHASE2. Conditions: IgG4 Related Disease
view source ↗Data sources
last refreshed 22m ago
Found something off?
same company · ±60 days · 6
- earningsBeOne Medicines Ltd. earningsNov 5, 2026
- earningsBeOne Medicines Ltd. earningsAug 5, 2026
- earningsBeOne Medicines Ltd. earningsMay 6, 2026
- phase 1 completionBG-89894: BeOne Medicines AG — BG-89894 (Phase I Trial Completion)Apr 30, 2026
- phase 1 initiationBGC-0979: BeOne Medicines AG — BGC-0979 (Phase I Trial Initiation)Apr 30, 2026
- approvalTEVIMBRA (TISLELIZUMAB-JSGR) — FDA approvalDec 9, 2025
related news · 8
- fiercebiotechDPHARM: How to address the clinical trial enrollment crisis?
- biospaceDrugmakers cherry pick launch regions as MFN creates 'policy environment like an earthquake'
- biospaceNovartis’ and BMS’ paused CAR T trials, RevMed’s pancreatic cancer approval, more MFN deals
- biopharma diveMid-cap biotechs join Trump’s latest round of drug pricing deals
- biospace9 midsize drugmakers climb aboard Trump’s MFN train
- fiercebiotechGenentech doubles down on ADC-resistant cancers with $1B DualityBio pact
- biospaceJazz scores front-line gastric cancer nod from FDA for ‘practice-changing’ Ziihera
- biopharma diveNew Jazz cancer drug approval could drive blockbuster sales
comments(0)
5-min edit window · permanent after that